Tom Dilling retweeted
Adriatic is the new Pacific as durva improves PFS and OS in LS-SCLC! So proud of my mentor Prof. Suresh Senan who lead this effort - lots to unpack here on PCI, RT schedule, and choice of platinum chemo #LCSM #RadOnc @drdavidpalma @bslotman @_ShankarSiva @DrewMoghanaki
Presented at #ESMO24:
Among patients with limited-stage small-cell lung cancer, overall and progression-free survival were significantly longer with durvalumab adjuvant therapy added to standard concurrent chemoradiotherapy. Full ADRIATIC trial results: nej.md/4d0eZ5m
Tom Dilling retweeted
Insightful discussion by @gerryhanna on 4 studies exploring the intensification of both surgical and non-surgical treatments for stage 3 NSCLC in the IO era
➡️ Provocative findings, though phase 3 data will be crucial
➡️ Urgent need for predictive biomarkers
#WCLC24
Tom Dilling retweeted
TOMORROW‼️‼️👀👀
If you are a medical student interested in learning more about Moffitt Rad Onc, please sign up at the link below.
Sign up link: docs.google.com/spreadsheets…
Tom Dilling retweeted
MS4s applying to Rad Onc 👀🔥
Excited to announce our upcoming Virtual Meet & Greet session!
If you are a medical student interested in learning more about Moffitt Rad Onc, please sign up at the link below.
Sign up link: docs.google.com/spreadsheets…
Tom Dilling retweeted
Now accepting volunteers interested in serving on committees &/or subcommittees for the Society year beginning 10/1. Read this ASTROblog post feat. President-elect @SameerKeoleMD, where he encourages members to think of how one can volunteer for the field. astro.org/blog/may-2024/volu…
Tom Dilling retweeted
I research women and far-right movements in the U.S. and Europe, including why women are increasingly likely to join and how their role has changed. This speech was a masterclass. 1/
Tom Dilling retweeted
Replying to @ielnaqa
@ielnaqa, @tom_dilling and Denis Dudas recently produced a publication entitled: "Improved outcome models with denoising diffusion" Please click here to see a copy of this publication:
pubmed.ncbi.nlm.nih.gov/3832…
Tom Dilling retweeted
@ml4onco congratulates @GhasemiPayman, @tom_dilling, @SA_Rosenberg and @ielnaqa on their newest publication: "Novel Dose Criteria for Lung Cancer SBRT to Improve Local Control in Patients Treated to 50 Gy/5 Fractions Using Deep Learning Methods..." pubmed.ncbi.nlm.nih.gov/3778…

















